NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference

NeoGenomics outlined a strategy to expand community-based precision oncology services, centered on next-generation sequencing, minimal residual disease testing and physician workflow tools. The initiative targets growth by enabling cancer care closer to patients' homes, but the article provides no financial targets, earnings data or quantified commercial impact.